Skip to main content
. Author manuscript; available in PMC: 2010 Apr 1.
Published in final edited form as: Arthritis Rheum. 2009 Apr;60(4):1076–1084. doi: 10.1002/art.24360

Fig. 1.

Fig. 1

(A) mRNA expression levels of MECP2 transcript variants (MECP2A and MECP2B) in B cells from lupus patients homozygous for the MECP2 risk haplotype (Risk) compared to patients homozygous for the protective haplotype (Protective). (B) Genes that are upregulated (104 genes) in lupus patients with the disease-associated MECP2 haplotype have significantly more CpG islands in their promoter region compared to downregulated genes (24 genes) (t= 2.07, p=0.04). (C) Confirmation of expression micraoarray data by real time RT PCR. The expression of 5 genes differentially expressed in B cells from 5 patients with the MECP2 risk haplotype (Risk) compared to 6 patients with the MECP2 protective haplotype (Protective) (p<0.05). (D, E) mRNA expression levels of CREB1 and HDAC1 in B cells from lupus patients homozygous for the MECP2 risk haplotype (Risk) compared to patients homozygous for the protective haplotype (Protective).